SEARCHMETA-ANALYSISglaucoma, ophthalmology

meta-analysis·glaucoma, ophthalmology, meta-analysis, systematic review·PMC10344552

Efficacy and safety of Fufang Xueshuantong Capsules in combination with conventional drugs in the treatment of glaucoma: A meta-analysis and trial sequential analysis

Medicine · 5 authors, 3 centres

AI SUMMARY

FIDELITY 100%

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

For safety, total drug-related adverse events were comparable between groups (0/92 in each), but TSA suggested more studies are needed.

Full summary

335 CHARS

For safety, total drug-related adverse events were comparable between groups (0/92 in each), but TSA suggested more studies are needed. Limitations include a small total sample size, unclear risk of bias, narrow inclusion criteria in some studies, and a treatment duration range of 21 to 90 days that may not reflect long-term effects.

STUDY TYPE

meta-analysis

SPECIALTY

glaucoma

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10344552

Efficacy and safety of Fufang Xueshuantong Capsules in combination with conventional drugs in the treatment of glaucoma: A meta-analysis and trial sequential analysis

Medicine

READ THE FULL PAPER

ABSTRACT

Background: Glaucoma is the leading cause of irreversible blindness worldwide. The aim of this study was to evaluate the efficacy and safety of Fufang Xueshuantong Capsules (FFXST) in combination with conventional drugs in the treatment of glaucoma using meta-analysis and trial sequential analysis (TSA). Methods: Clinical trials of FFXST for glaucoma were identified in 8 databases until November 2022, and studies were included for meta-analysis and trial sequential analysis. Results: In terms of efficacy endpoints, meta-analysis showed that the combination group of FFXST significantly improved clinical effective rate (RR 1.29, 95% CI 1.20–1.39, P < .00001), visual function (MD 0.04, 95% CI 0.04–0.05, P < .00001), light sensitivity (MD 6.07, 95% CI 4.63–7.51, P < .00001), end-systolic blood flow velocity (MD 2.68, 95% CI 2.19–3.16, P < .00001) and end-diastolic blood flow velocity (MD 2.07, 95% CI 1.86–2.28, P < .00001), and significantly reduced total gray-scale value (MD −64.38, 95% CI −69.08 to −59.68, P < .00001) and defect of visual field (MD −3.40, 95% CI −4.11 to −2.69, P < .00001) compared with the conventional regimen group, while the pulsatility index and resistance index were comparable. The TSA indicated that these benefits were conclusive. In terms of safety endpoints, meta-analysis demonstrated that total drug-related adverse events in the combination group of FFXST were comparable to those in the conventional regimen group, with TSA showing that more studies are needed to validate the current results. Conclusion: FFXST may be a safety and effective supplementary strategy for the treatment of glaucoma, which is worthy of further research. Keywords: Fufang Xueshuantong Capsules, glaucoma, meta-analysis, trial sequential analysis

CITATION EXPORT

Zhicheng Zeng, Pengfei Jiang, Pei Liu et al.. Efficacy and safety of Fufang Xueshuantong Capsules in combination with conventional drugs in the treatment of glaucoma: A meta-analysis and trial sequential analysis. Medicine. (2023). https://doi.org/10.1097/MD.0000000000034202

AUTHORS

5 · 3 CENTRES

Zhicheng Zeng, Pengfei Jiang, Pei Liu, Jun Peng, Qinghua Peng

a Department of Ophthalmology, the First People’s Hospital of Guiyang, Chenzhou, China
b Hunan University of Chinese Medicine, Changsha, China
c The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, China.